Dynabac

Company
Sanofi-aventis

Approval Status
Approved March 1998

Treatment for
acute bacterial exacerbations

Areas
Dermatology / Plastic Surgery , Immune System , Respiratory

Dynabac, a member of the newer macrolide group of antibiotics, has received approval for expanded coverage within certain indications, including the treatment of acute bacterial exacerbations of chronic bronchitis and uncomplicated skin and skin structure infections. Dynabac remains a once-a-day therapy.

The most common side effects were gastrointestinal, including abdominal pain, nausea, and diarrhea.

Dynabac Drug Information

The Dynabac drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top